Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
Department of
Microbiology1 and First Department of
Internal Medicine,
Received 27 July 1998/Returned for modification 5 November
1998/Accepted 27 February 1999
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated
for their in vitro antimicrobial activities against 44 strains of
Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of
isolates are inhibited for these drugs were lower (0.002 and 0.008 µg/ml, respectively) than those of amoxicillin and rifampin for
H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be
useful for the eradication of H. pylori infections.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro Anti-Helicobacter pylori
Activities of New Rifamycin Derivatives, KRM-1648 and
KRM-1657
*
Corresponding author. Mailing address: Department of
Microbiology, Yamaguchi University School of Medicine, 1144, kogushi, Ube, Yamaguchi 755-8505, Japan. Phone: 81-836-22-2226. Fax:
81-836-22-2227. E-mail:
nakazawa{at}po.cc.yamaguchi-u.ac.jp.
Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |